In a study published in Nature Medicine, CTD2 investigators modeled colorectal cancer in primary organoids derived from mouse colon. They used the organoid system to functionally study Insulin-…
In the News
Read the latest news on OCG to stay up-to-date on new research findings and important announcements.
CTD²
CTD2 bioinformaticians at Memorial Sloan Kettering Cancer Center developed an analysis tool called Statius to identify potential therapeutics to target patient-specific vulnerabilities. In tumors…
CTD²
Evaluation of Dependency DifferentialitY (EDDY) provides an alternative approach to differential expression-based analyses of data generated under multiple conditions. It was developed by…
CTD²
Despite non-small cell lung cancers (NSCLC) being one of the most common cancers, current treatment strategies are limited and survival rates are extremely low. CTD2 investigators at the…
CTD²
CTD2 researchers at University of Texas Southwestern Medical Center determined the structure and biosynthetic pathways of a family of natural compounds that inhibit the discoidin domain receptor 2…
CTD²
A review by the CTD2 Center at Emory University entitled “Targeting protein-protein interactions as an anticancer strategy” was published [Epub ahead of print] on May 28 in the journal Trends in…
CGCI
Researchers from British Columbia Cancer Agency used whole genome sequencing to analyze 40 DLBCL cases and 13 cell lines in order to fill in the gaps of the complex landscape of DLBCL genomes.…
TARGET
TARGET researchers presented their work on pediatric cancers at the AACR Annual Meeting 2013. The entire TARGET session is available free to the public on the AACR website:
CTD²
Dr. Daniela Gerhard Introduces Cancer Target Discovery and Development (CTD2) Scientific Session at AACR 2013
CGCI
Through RNA-seq and targeted exon sequencing analysis, investigators working in the CGCI program discovered FOXO1 frequently mutated in diffuse large B-cell lymphoma (DLBCL) cases. FOXO1…